Search
Total Rewards At a Glance.pdf
Patient Assistance Program
Patient Assistance Program
IT at BI
Discover firsthand what IT does at BI #IdoIT
Data Privacy
Data Privacy
Accessibility Statement
Accessibility Statement
Ann-Kathrin Koller
Career choices, culture, the future and more with Ann-Kathrin Koller.
Our Respiratory Partnering Interests
Our Respiratory Partnering Interests
Our ‘Target, Repair, Prevent’ Approach to Inflammatory Disease Research
Our ‘Target, Repair, Prevent’ Approach to Inflammatory Disease Research
Delving into Diabetic Retinopathy
Delving into Diabetic Retinopathy
Our Grass Roots Initiatives
Our Grass Roots Initiatives
PAP Program information
partnering-immunology-respiratory-diseases.pdf
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Protein Degraders: Changing the Game in Cancer Drug Discovery
Protein Degraders: Changing the Game in Cancer Drug Discovery
BI Cares Financial Contributions Program
BI Cares Financial Contributions Program
When Passion Starts as a Family Value and Continues as a Work Value
Discover who inspires members of our LatinX Business Resource Group.
My journey to advance diversity, equity and inclusion in the workplace
Hear from one of our employees, Tanisha Archer-Parkes, on the importance of diversity in the workplace and continuing to move toward a more inclusive and accepting society.
U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes
U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes
Women Inspiring Women: 5 questions for 6 women
Women Inspiring Women: 5 questions for 6 women
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
Results for Jardiance® (empaglifozin) | BI US
Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.
Phase III EMPA-KIDNEY trial will stop early
The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.
Our forward-looking approach drives breakthroughs
Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
Fur-ever homes: How pet shelters and fosters have met the challenge of the pandemic
Pet shelters impacted by the COVID-19 pandemic have benefitted from the Stay Home and Foster program, which connects shelter pets with foster homes.